James D Moffatt

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. pmc Effects of inhaled thrombin receptor agonists in mice
    James D Moffatt
    Sackler Institute of Pulmonary Pharmacology, GKT School of Biomedical Sciences, Kings College London, 5th Floor Hodgkin Building, Guy s Campus, London SE1 9RT
    Br J Pharmacol 143:269-75. 2004
  2. ncbi request reprint Protease-activated receptor-2 activating peptide SLIGRL inhibits bacterial lipopolysaccharide-induced recruitment of polymorphonuclear leukocytes into the airways of mice
    James D Moffatt
    Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia
    Am J Respir Cell Mol Biol 26:680-4. 2002
  3. ncbi request reprint Protease-activated receptor-2 peptides activate neurokinin-1 receptors in the mouse isolated trachea
    Hugh T Abey
    Department of Pharmacology, The University of Melbourne, Parkville, Australia
    J Pharmacol Exp Ther 317:598-605. 2006
  4. pmc Enzymatic activation of endothelial protease-activated receptors is dependent on artery diameter in human and porcine isolated coronary arteries
    Justin R Hamilton
    Department of Pharmacology, University of Melbourne, Victoria 3010, Australia
    Br J Pharmacol 136:492-501. 2002
  5. ncbi request reprint Pharmacologically distinct intracellular calcium pools regulate tonic and oscillatory responses in porcine thoracic duct
    James D Moffatt
    Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia
    J Cardiovasc Pharmacol 43:83-92. 2004
  6. pmc Role of the epithelium and acetylcholine in mediating the contraction to 5-hydroxytryptamine in the mouse isolated trachea
    James D Moffatt
    Sackler Institute of Pulmonary Pharmacology, King s College London, London
    Br J Pharmacol 141:1159-66. 2004
  7. pmc Pharmacological characterisation of the adenosine receptor mediating increased ion transport in the mouse isolated trachea and the effect of allergen challenge
    Kristin N Kornerup
    The Sackler Institute of Pulmonary Pharmacology, GKT School of Biomedical Sciences, 5th Floor Hodgkin Building, Guy s Campus, London SE1 1UL
    Br J Pharmacol 144:1011-6. 2005
  8. ncbi request reprint Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice
    James D Moffatt
    The Sackler Institute of Pulmonary Pharmacology, King s College London, Guy s Campus, London, UK
    FASEB J 20:1877-9. 2006

Collaborators

  • Justin R Hamilton
  • Hugh T Abey
  • Kristin N Kornerup
  • Rowan W Balzary
  • Thomas M Cocks
  • David P Fairlie
  • Clive P Page

Detail Information

Publications8

  1. pmc Effects of inhaled thrombin receptor agonists in mice
    James D Moffatt
    Sackler Institute of Pulmonary Pharmacology, GKT School of Biomedical Sciences, Kings College London, 5th Floor Hodgkin Building, Guy s Campus, London SE1 9RT
    Br J Pharmacol 143:269-75. 2004
    ..In conclusion, exogenous thrombin has only a modest acute inflammatory action in the lung that appears to be mediated by PAR(4) and involve release of TNF-alpha from an unknown source...
  2. ncbi request reprint Protease-activated receptor-2 activating peptide SLIGRL inhibits bacterial lipopolysaccharide-induced recruitment of polymorphonuclear leukocytes into the airways of mice
    James D Moffatt
    Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia
    Am J Respir Cell Mol Biol 26:680-4. 2002
    ..These findings suggest that PAR2 agonists may be useful therapeutic molecules in pulmonary inflammatory diseases...
  3. ncbi request reprint Protease-activated receptor-2 peptides activate neurokinin-1 receptors in the mouse isolated trachea
    Hugh T Abey
    Department of Pharmacology, The University of Melbourne, Parkville, Australia
    J Pharmacol Exp Ther 317:598-605. 2006
    ..Such a potential lack of specificity of these commonly used peptides needs to be considered when roles for PAR(2) in airway function in health and disease are determined...
  4. pmc Enzymatic activation of endothelial protease-activated receptors is dependent on artery diameter in human and porcine isolated coronary arteries
    Justin R Hamilton
    Department of Pharmacology, University of Melbourne, Victoria 3010, Australia
    Br J Pharmacol 136:492-501. 2002
    ....
  5. ncbi request reprint Pharmacologically distinct intracellular calcium pools regulate tonic and oscillatory responses in porcine thoracic duct
    James D Moffatt
    Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia
    J Cardiovasc Pharmacol 43:83-92. 2004
    ....
  6. pmc Role of the epithelium and acetylcholine in mediating the contraction to 5-hydroxytryptamine in the mouse isolated trachea
    James D Moffatt
    Sackler Institute of Pulmonary Pharmacology, King s College London, London
    Br J Pharmacol 141:1159-66. 2004
    ..This phenomenon should be borne in mind in when interpreting studies of murine models of airway disease...
  7. pmc Pharmacological characterisation of the adenosine receptor mediating increased ion transport in the mouse isolated trachea and the effect of allergen challenge
    Kristin N Kornerup
    The Sackler Institute of Pulmonary Pharmacology, GKT School of Biomedical Sciences, 5th Floor Hodgkin Building, Guy s Campus, London SE1 1UL
    Br J Pharmacol 144:1011-6. 2005
    ..These results suggest that the A2B receptor mediates the I(SC) response to adenosine in the mouse trachea. This receptor does not appear to be regulated in a standard asthma model...
  8. ncbi request reprint Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice
    James D Moffatt
    The Sackler Institute of Pulmonary Pharmacology, King s College London, Guy s Campus, London, UK
    FASEB J 20:1877-9. 2006
    ..Therefore, CRF(2) agonists appear to have both bronchorelaxant and anti-inflammatory activities and might represent an interesting therapeutic approach to the treatment of inflammatory lung diseases...